BioCryst Pharmaceuticals and Idera Pharmaceuticals have entered into a definitive merger agreement to form a rare disease-focused company under a new name. The combined company has a pipeline of four late- and mid-stage candidates as well as a number of early phase programmes and an estimated US$243 M in net cash. Shares in both companies fell after the announcement of the merger suggesting investor concerns about the prospects of the deal.